Q-Line Biotech Limited (NSE:QLINE)

Market Cap	14.27B
Revenue (ttm)	3.42B +12.3%
Net Income	567.13M +1.3%
EPS	35.41 -3.5%
Shares Out	23.33M
PE Ratio	17.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	72,000
Open	605.05
Previous Close	601.75
Day's Range	601.00 - 635.95
52-Week Range	431.00 - 735.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Q-Line Biotech

Q-Line Biotech Limited develops, manufactures, and markets various reagents and consumables in India and internationally. It offers reagents and diagnostic kits, analysers, point-of-care devices, molecular diagnostics for applications in immunodiagnostics, hematology, molecular diagnostics, clinical chemistry, and others, as well as in vitro testing of human samples, supporting disease prediction, prevention, diagnosis, monitoring, and health status evaluation. The company also provides diagnostic equipment comprising analyzers, point-of-care d...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2010
• Employees: 357
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: QLINE

Financial Performance

In fiscal year 2026, Q-Line Biotech's revenue was 3.42 billion, an increase of 9.13% compared to the previous year's 3.13 billion. Earnings were 567.13 million, an increase of 56.75%.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 14, 2026

Data Sources Report a data error